European Union: New EU Rules For Medical Devices

After four years of negotiations, European lawmakers agreed on June 15 on a new EU Medical Devices Regulation (MDR).

The MDR is the equivalent to the FDA's CDRH regulations in the United States and essentially specifies the applicable rules when importing medical devices into Europe, which is the world's second-largest device market. Rules relate, for example, to product classification; quality system standards; pre-market authorization; and reporting of adverse events.

The final version of the MDR – a hefty 352 pages – was published on June 27 and is now reviewed by the EU's legal editor for drafting or law-technical errors. It then needs to be translated into all EU member languages, followed by formal publication. After publication, expected in late 2016 or early 2017, there will be a three-year transition period as the medical device industry will need time to comply with the new requirements.

Some of the key changes are:

New obligations on companies

Unique Device Identifiers (UDI) will be introduced gradually, similar to the system in place for the US market, to increase traceability of devices through the supply chain, and to facilitate product recalls if needed (similarly, all economic operators will have a single registration number or SRN). This may lead to the manufacturer having to change the product label (barcoding). Manufacturer will also be required to engage a medical device expert responsible for regulatory compliance management. Manufacturers will be required to take out an insurance policy for possible liability claims for defective devices.

Other operators in the supply chain aside from the manufacturer face also new obligations. For example, importers and distributors will need to verify compliance of the device; inform competent authorities in case of non-compliance; etc. This is in line with the greater emphasis in the MDR on companies having to follow up on quality, performance and safety of devices after they are placed on the market. Even the so-called for-profit, private 'notified bodies' (empowered at national level to approve new devices) will have the right and duty to carry out unannounced on-site audits and to conduct physical or laboratory tests on medical devices to ensure continuous compliance.

Pre-market approval, however, remains critical as well, and will become more 'frontloaded' than under the current system. The essential conformity requirements – now called 'general safety and performance requirements' – have grown, so manufacturers will need to review and update their existing quality systems and technical files. They will also need to be more active in collecting data to support safety and efficacy. This is certainly the case for clinical evaluation of devices, especially high-risk devices such as implantable devices. Increased post-market surveillance is also relevant in this context as manufacturers will have to draft so-called PMCFs (Post-Market Clinical Follow-Up) and PSUs (Periodic Safety Update reports) to ensure safety and performance throughout the expected lifetime of the device.

Other regulatory requirements will come into place in relation to a variety of business practices, such as, relabeling/repackaging; reprocessing of single-use devices; hospital produced ("home brew") devices.

Extended product scope

Certain products currently not qualified as a medical device, will now fall under the definition of a medical device and thus within the scope of the MDR such as products used for cleaning, disinfecting or sterilizing other medical devices (e.g. endoscope washer/disinfector) or devices for purposes of control or support of conception (e.g. condom). Their accessories will also be covered by the MDR (e.g. devices used to position or remove invasive or implantable contraceptives).

Even products without intended medical purposes but rather aesthetic or cosmetic ones such as contact lenses, liposuction or laser equipment for skin treatment are considered a medical device. The European Commission can add other products to this category and has to adopt so-called common specifications detailing safety and performance requirements for these products.

Whilst general purpose software or lifestyle/wellbeing software is not considered a medical device, all software and mobile health apps designed for any of the purposes included in the definition of medical devices (e.g. forecasting or prognosis of diseases) will be regulated.

In vitro diagnostics are not subject to the MDR but fall under the newly adopted stand-alone regulation.

New classification rules

Medical devices are assigned to one of the four regulatory classes based on the intended purpose of the device and the risk the device poses to the patient and/or the user. Some devices will be "up-classified" according to new classification rules which in turn may lead to a new conformity assessment having to be carried out for the device concerned. This may be the case for nanotechnology and substance-based medical devices, specific orthopaedic implants, life-saving active medical devices, etc.

Increased access and transparency of data

The European Database for Medical Devices (Eudamed) – the equivalent of the US's MAUDE database – holds information on medical devices collected from the European Commission and national authorities. Under current rules, only these authorities can access Eudamed. However, Eudamed access will be expanded now (partially) to market participants, incl. notified bodies; manufacturers; patients; healthcare professionals and the public. The accessible medical device data will encompass UDI and SRN data; post-market surveillance data; conformity assessment applications; safety and clinical performance summaries.

Preparing for the new MDR

There is no grandfathering from CE marked medical devices under the current medical device directive to the new MDR. So a conformity assessment will be required for all existing and new devices. While medical device companies have 3 years to become compliant, they should begin implementation of the adjustments under the MDR as soon as possible. This transition plan includes:

  • prepare a gap assessment to juxtapose existing obligations against new or changed obligations under the MDR, especially in case of a possible new status and risk class for the device;
  • review business agreements and processes to take into account the different roles and responsibility of market operators and supply chain regulation;
  • update technical documentation, systems and processes regarding safety and performance requirements including labelling requirements (e.g. SRN, UDI);
  • keep track of new or revised guidance issued by the European Commission and regulatory acts which further implement the MDR (and also old law that remains applicable)

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
24 Oct 2017, Seminar, Los Angeles, United States

Presented by The American Bar Association White Collar Crime Committee.

24 Oct 2017, Conference, Los Angeles, United States

Corporate transactions are not just in the domain of M&A corporate attorneys. This program will cover the important role of employment and benefits counsel in shaping mergers and acquisitions. The presenters will provide practical guidance on conducting due diligence of labor, employment, employee benefits and executive compensation arrangements of target companies.

25 Oct 2017, Business Breakfast, New York, United States

Please join us for a complimentary breakfast program and networking with private equity investment banking professionals to discuss private equity activity and prospective deal flow opportunities in the technology industry.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.